Willa D Brenowitz1, Rebecca A Hubbard2, C Dirk Keene3, Stephen E Hawes4, W T Longstreth5, Randy L Woltjer6, Walter A Kukull7. 1. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA. Electronic address: wbrenow@u.washington.edu. 2. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Pathology, University of Washington, Seattle, WA, USA. 4. Department of Epidemiology, University of Washington, Seattle, WA, USA. 5. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA; Department of Neurology, University of Washington, Seattle, WA, USA. 6. Department of Pathology, Oregon Health and Science University, Portland, OR, USA. 7. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA.
Abstract
INTRODUCTION: Whether co-occurring neuropathologies interact or independently affect clinical disease progression is uncertain. We estimated rates of clinical progression and tested whether associations between clinical progression and Alzheimer's disease neuropathology (ADNP) were modified by co-occurring Lewy body disease (LBD) or vascular brain injury (VBI). METHODS: Linear mixed effects models evaluated longitudinal trends in the Clinical Dementia Rating Scale Sum of Boxes on 2046 autopsied participants seen at a U.S. Alzheimer's Disease Center. RESULTS: Annual clinical progression was slightly faster for ADNP + LBD compared with ADNP only (P = .06) and slightly slower for ADNP + VBI (P = .003). Differences in progression were less than expected if each neuropathology independently contributed to progression; ADNP interacted with LBD (P = .002) and VBI (P = .003). In secondary models, the effect of additional pathologies on clinical progression was greater in those with intermediate compared with high levels of ADNP. DISCUSSION: The impact of co-occurring pathologies on progression may depend on severity of ADNP.
INTRODUCTION: Whether co-occurring neuropathologies interact or independently affect clinical disease progression is uncertain. We estimated rates of clinical progression and tested whether associations between clinical progression and Alzheimer's disease neuropathology (ADNP) were modified by co-occurring Lewy body disease (LBD) or vascular brain injury (VBI). METHODS: Linear mixed effects models evaluated longitudinal trends in the Clinical Dementia Rating Scale Sum of Boxes on 2046 autopsied participants seen at a U.S. Alzheimer's Disease Center. RESULTS: Annual clinical progression was slightly faster for ADNP + LBD compared with ADNP only (P = .06) and slightly slower for ADNP + VBI (P = .003). Differences in progression were less than expected if each neuropathology independently contributed to progression; ADNP interacted with LBD (P = .002) and VBI (P = .003). In secondary models, the effect of additional pathologies on clinical progression was greater in those with intermediate compared with high levels of ADNP. DISCUSSION: The impact of co-occurring pathologies on progression may depend on severity of ADNP.
Authors: Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery Journal: Ann N Y Acad Sci Date: 2002-11 Impact factor: 5.691
Authors: M L Kraybill; E B Larson; D W Tsuang; L Teri; W C McCormick; J D Bowen; W A Kukull; J B Leverenz; M M Cherrier Journal: Neurology Date: 2005-06-28 Impact factor: 9.910
Authors: Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack Journal: Brain Date: 2015-01-15 Impact factor: 13.501
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Lilah M Besser; Walter A Kukull; Merilee A Teylan; Eileen H Bigio; Nigel J Cairns; Julia K Kofler; Thomas J Montine; Julie A Schneider; Peter T Nelson Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685
Authors: Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski Journal: J Appl Lab Med Date: 2020-01-01
Authors: Rizwan S Akhtar; Joseph P Licata; Kelvin C Luk; Leslie M Shaw; John Q Trojanowski; Virginia M-Y Lee Journal: J Neurochem Date: 2018-06-10 Impact factor: 5.372
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull Journal: Neurology Date: 2017-09-22 Impact factor: 9.910
Authors: Tanis J Ferman; Naoya Aoki; Bradley F Boeve; Jeremiah A Aakre; Kejal Kantarci; Jonathan Graff-Radford; Joseph E Parisi; Jay A Van Gerpen; Neill R Graff-Radford; Ryan J Uitti; Otto Pedraza; Melissa E Murray; Zbigniew K Wszolek; R Ross Reichard; Julie A Fields; Owen A Ross; David S Knopman; Ronald C Petersen; Dennis W Dickson Journal: Neurology Date: 2020-06-19 Impact factor: 9.910